Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Ovarian Cancer Diagnostic Market

ID: MRFR/HC/27658-HCR
128 Pages
Rahul Gotadki
Last Updated: April 24, 2026

Ovarian Cancer Diagnostics Market Research Report: Size, Share, Trend Analysis By Test Type (Biomarker Tests, Imaging Tests, Genetic Tests, Pathology Tests), By Biomarker (CA-125, HE4, ROMA, OVX1, PAX2, MMP7), By Imaging modality (Ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), By Genetic mutation (BRCA1, BRCA2, TP53, PTEN, ARID1A, CHEK2) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Ovarian Cancer Diagnostic Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Test Type (USD Billion)
  49.     4.1.1 Biomarker Tests
  50.     4.1.2 Imaging Tests
  51.     4.1.3 Genetic Tests
  52.     4.1.4 Pathology Tests
  53.   4.2 Healthcare, BY Biomarker (USD Billion)
  54.     4.2.1 CA-125
  55.     4.2.2 HE4
  56.     4.2.3 ROMA
  57.     4.2.4 OVX1
  58.     4.2.5 PAX2
  59.     4.2.6 MMP7
  60.   4.3 Healthcare, BY Imaging Modality (USD Billion)
  61.     4.3.1 Ultrasound
  62.     4.3.2 Computed Tomography (CT)
  63.     4.3.3 Magnetic Resonance Imaging (MRI)
  64.     4.3.4 Positron Emission Tomography (PET)
  65.   4.4 Healthcare, BY Genetic Mutation (USD Billion)
  66.     4.4.1 BRCA1
  67.     4.4.2 BRCA2
  68.     4.4.3 TP53
  69.     4.4.4 PTEN
  70.     4.4.5 ARID1A
  71.     4.4.6 CHEK2
  72.   4.5 Healthcare, BY Region (USD Billion)
  73.     4.5.1 North America
  74.       4.5.1.1 US
  75.       4.5.1.2 Canada
  76.     4.5.2 Europe
  77.       4.5.2.1 Germany
  78.       4.5.2.2 UK
  79.       4.5.2.3 France
  80.       4.5.2.4 Russia
  81.       4.5.2.5 Italy
  82.       4.5.2.6 Spain
  83.       4.5.2.7 Rest of Europe
  84.     4.5.3 APAC
  85.       4.5.3.1 China
  86.       4.5.3.2 India
  87.       4.5.3.3 Japan
  88.       4.5.3.4 South Korea
  89.       4.5.3.5 Malaysia
  90.       4.5.3.6 Thailand
  91.       4.5.3.7 Indonesia
  92.       4.5.3.8 Rest of APAC
  93.     4.5.4 South America
  94.       4.5.4.1 Brazil
  95.       4.5.4.2 Mexico
  96.       4.5.4.3 Argentina
  97.       4.5.4.4 Rest of South America
  98.     4.5.5 MEA
  99.       4.5.5.1 GCC Countries
  100.       4.5.5.2 South Africa
  101.       4.5.5.3 Rest of MEA
  102. 5 SECTION V: COMPETITIVE ANALYSIS
  103.   5.1 Competitive Landscape
  104.     5.1.1 Overview
  105.     5.1.2 Competitive Analysis
  106.     5.1.3 Market share Analysis
  107.     5.1.4 Major Growth Strategy in the Healthcare
  108.     5.1.5 Competitive Benchmarking
  109.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  110.     5.1.7 Key developments and growth strategies
  111.       5.1.7.1 New Product Launch/Service Deployment
  112.       5.1.7.2 Merger & Acquisitions
  113.       5.1.7.3 Joint Ventures
  114.     5.1.8 Major Players Financial Matrix
  115.       5.1.8.1 Sales and Operating Income
  116.       5.1.8.2 Major Players R&D Expenditure. 2023
  117.   5.2 Company Profiles
  118.     5.2.1 Roche (CH)
  119.       5.2.1.1 Financial Overview
  120.       5.2.1.2 Products Offered
  121.       5.2.1.3 Key Developments
  122.       5.2.1.4 SWOT Analysis
  123.       5.2.1.5 Key Strategies
  124.     5.2.2 Abbott (US)
  125.       5.2.2.1 Financial Overview
  126.       5.2.2.2 Products Offered
  127.       5.2.2.3 Key Developments
  128.       5.2.2.4 SWOT Analysis
  129.       5.2.2.5 Key Strategies
  130.     5.2.3 Thermo Fisher Scientific (US)
  131.       5.2.3.1 Financial Overview
  132.       5.2.3.2 Products Offered
  133.       5.2.3.3 Key Developments
  134.       5.2.3.4 SWOT Analysis
  135.       5.2.3.5 Key Strategies
  136.     5.2.4 Siemens Healthineers (DE)
  137.       5.2.4.1 Financial Overview
  138.       5.2.4.2 Products Offered
  139.       5.2.4.3 Key Developments
  140.       5.2.4.4 SWOT Analysis
  141.       5.2.4.5 Key Strategies
  142.     5.2.5 Bristol-Myers Squibb (US)
  143.       5.2.5.1 Financial Overview
  144.       5.2.5.2 Products Offered
  145.       5.2.5.3 Key Developments
  146.       5.2.5.4 SWOT Analysis
  147.       5.2.5.5 Key Strategies
  148.     5.2.6 Myriad Genetics (US)
  149.       5.2.6.1 Financial Overview
  150.       5.2.6.2 Products Offered
  151.       5.2.6.3 Key Developments
  152.       5.2.6.4 SWOT Analysis
  153.       5.2.6.5 Key Strategies
  154.     5.2.7 Guardant Health (US)
  155.       5.2.7.1 Financial Overview
  156.       5.2.7.2 Products Offered
  157.       5.2.7.3 Key Developments
  158.       5.2.7.4 SWOT Analysis
  159.       5.2.7.5 Key Strategies
  160.     5.2.8 F. Hoffmann-La Roche (CH)
  161.       5.2.8.1 Financial Overview
  162.       5.2.8.2 Products Offered
  163.       5.2.8.3 Key Developments
  164.       5.2.8.4 SWOT Analysis
  165.       5.2.8.5 Key Strategies
  166.     5.2.9 Genomic Health (US)
  167.       5.2.9.1 Financial Overview
  168.       5.2.9.2 Products Offered
  169.       5.2.9.3 Key Developments
  170.       5.2.9.4 SWOT Analysis
  171.       5.2.9.5 Key Strategies
  172.   5.3 Appendix
  173.     5.3.1 References
  174.     5.3.2 Related Reports
  175. 6 LIST OF FIGURES
  176.   6.1 MARKET SYNOPSIS
  177.   6.2 NORTH AMERICA MARKET ANALYSIS
  178.   6.3 US MARKET ANALYSIS BY TEST TYPE
  179.   6.4 US MARKET ANALYSIS BY BIOMARKER
  180.   6.5 US MARKET ANALYSIS BY IMAGING MODALITY
  181.   6.6 US MARKET ANALYSIS BY GENETIC MUTATION
  182.   6.7 CANADA MARKET ANALYSIS BY TEST TYPE
  183.   6.8 CANADA MARKET ANALYSIS BY BIOMARKER
  184.   6.9 CANADA MARKET ANALYSIS BY IMAGING MODALITY
  185.   6.10 CANADA MARKET ANALYSIS BY GENETIC MUTATION
  186.   6.11 EUROPE MARKET ANALYSIS
  187.   6.12 GERMANY MARKET ANALYSIS BY TEST TYPE
  188.   6.13 GERMANY MARKET ANALYSIS BY BIOMARKER
  189.   6.14 GERMANY MARKET ANALYSIS BY IMAGING MODALITY
  190.   6.15 GERMANY MARKET ANALYSIS BY GENETIC MUTATION
  191.   6.16 UK MARKET ANALYSIS BY TEST TYPE
  192.   6.17 UK MARKET ANALYSIS BY BIOMARKER
  193.   6.18 UK MARKET ANALYSIS BY IMAGING MODALITY
  194.   6.19 UK MARKET ANALYSIS BY GENETIC MUTATION
  195.   6.20 FRANCE MARKET ANALYSIS BY TEST TYPE
  196.   6.21 FRANCE MARKET ANALYSIS BY BIOMARKER
  197.   6.22 FRANCE MARKET ANALYSIS BY IMAGING MODALITY
  198.   6.23 FRANCE MARKET ANALYSIS BY GENETIC MUTATION
  199.   6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE
  200.   6.25 RUSSIA MARKET ANALYSIS BY BIOMARKER
  201.   6.26 RUSSIA MARKET ANALYSIS BY IMAGING MODALITY
  202.   6.27 RUSSIA MARKET ANALYSIS BY GENETIC MUTATION
  203.   6.28 ITALY MARKET ANALYSIS BY TEST TYPE
  204.   6.29 ITALY MARKET ANALYSIS BY BIOMARKER
  205.   6.30 ITALY MARKET ANALYSIS BY IMAGING MODALITY
  206.   6.31 ITALY MARKET ANALYSIS BY GENETIC MUTATION
  207.   6.32 SPAIN MARKET ANALYSIS BY TEST TYPE
  208.   6.33 SPAIN MARKET ANALYSIS BY BIOMARKER
  209.   6.34 SPAIN MARKET ANALYSIS BY IMAGING MODALITY
  210.   6.35 SPAIN MARKET ANALYSIS BY GENETIC MUTATION
  211.   6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE
  212.   6.37 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER
  213.   6.38 REST OF EUROPE MARKET ANALYSIS BY IMAGING MODALITY
  214.   6.39 REST OF EUROPE MARKET ANALYSIS BY GENETIC MUTATION
  215.   6.40 APAC MARKET ANALYSIS
  216.   6.41 CHINA MARKET ANALYSIS BY TEST TYPE
  217.   6.42 CHINA MARKET ANALYSIS BY BIOMARKER
  218.   6.43 CHINA MARKET ANALYSIS BY IMAGING MODALITY
  219.   6.44 CHINA MARKET ANALYSIS BY GENETIC MUTATION
  220.   6.45 INDIA MARKET ANALYSIS BY TEST TYPE
  221.   6.46 INDIA MARKET ANALYSIS BY BIOMARKER
  222.   6.47 INDIA MARKET ANALYSIS BY IMAGING MODALITY
  223.   6.48 INDIA MARKET ANALYSIS BY GENETIC MUTATION
  224.   6.49 JAPAN MARKET ANALYSIS BY TEST TYPE
  225.   6.50 JAPAN MARKET ANALYSIS BY BIOMARKER
  226.   6.51 JAPAN MARKET ANALYSIS BY IMAGING MODALITY
  227.   6.52 JAPAN MARKET ANALYSIS BY GENETIC MUTATION
  228.   6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE
  229.   6.54 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER
  230.   6.55 SOUTH KOREA MARKET ANALYSIS BY IMAGING MODALITY
  231.   6.56 SOUTH KOREA MARKET ANALYSIS BY GENETIC MUTATION
  232.   6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE
  233.   6.58 MALAYSIA MARKET ANALYSIS BY BIOMARKER
  234.   6.59 MALAYSIA MARKET ANALYSIS BY IMAGING MODALITY
  235.   6.60 MALAYSIA MARKET ANALYSIS BY GENETIC MUTATION
  236.   6.61 THAILAND MARKET ANALYSIS BY TEST TYPE
  237.   6.62 THAILAND MARKET ANALYSIS BY BIOMARKER
  238.   6.63 THAILAND MARKET ANALYSIS BY IMAGING MODALITY
  239.   6.64 THAILAND MARKET ANALYSIS BY GENETIC MUTATION
  240.   6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE
  241.   6.66 INDONESIA MARKET ANALYSIS BY BIOMARKER
  242.   6.67 INDONESIA MARKET ANALYSIS BY IMAGING MODALITY
  243.   6.68 INDONESIA MARKET ANALYSIS BY GENETIC MUTATION
  244.   6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE
  245.   6.70 REST OF APAC MARKET ANALYSIS BY BIOMARKER
  246.   6.71 REST OF APAC MARKET ANALYSIS BY IMAGING MODALITY
  247.   6.72 REST OF APAC MARKET ANALYSIS BY GENETIC MUTATION
  248.   6.73 SOUTH AMERICA MARKET ANALYSIS
  249.   6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE
  250.   6.75 BRAZIL MARKET ANALYSIS BY BIOMARKER
  251.   6.76 BRAZIL MARKET ANALYSIS BY IMAGING MODALITY
  252.   6.77 BRAZIL MARKET ANALYSIS BY GENETIC MUTATION
  253.   6.78 MEXICO MARKET ANALYSIS BY TEST TYPE
  254.   6.79 MEXICO MARKET ANALYSIS BY BIOMARKER
  255.   6.80 MEXICO MARKET ANALYSIS BY IMAGING MODALITY
  256.   6.81 MEXICO MARKET ANALYSIS BY GENETIC MUTATION
  257.   6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE
  258.   6.83 ARGENTINA MARKET ANALYSIS BY BIOMARKER
  259.   6.84 ARGENTINA MARKET ANALYSIS BY IMAGING MODALITY
  260.   6.85 ARGENTINA MARKET ANALYSIS BY GENETIC MUTATION
  261.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE
  262.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER
  263.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMAGING MODALITY
  264.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY GENETIC MUTATION
  265.   6.90 MEA MARKET ANALYSIS
  266.   6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE
  267.   6.92 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER
  268.   6.93 GCC COUNTRIES MARKET ANALYSIS BY IMAGING MODALITY
  269.   6.94 GCC COUNTRIES MARKET ANALYSIS BY GENETIC MUTATION
  270.   6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE
  271.   6.96 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER
  272.   6.97 SOUTH AFRICA MARKET ANALYSIS BY IMAGING MODALITY
  273.   6.98 SOUTH AFRICA MARKET ANALYSIS BY GENETIC MUTATION
  274.   6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE
  275.   6.100 REST OF MEA MARKET ANALYSIS BY BIOMARKER
  276.   6.101 REST OF MEA MARKET ANALYSIS BY IMAGING MODALITY
  277.   6.102 REST OF MEA MARKET ANALYSIS BY GENETIC MUTATION
  278.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  279.   6.104 RESEARCH PROCESS OF MRFR
  280.   6.105 DRO ANALYSIS OF HEALTHCARE
  281.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  282.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  283.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  284.   6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
  285.   6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion)
  286.   6.111 HEALTHCARE, BY BIOMARKER, 2024 (% SHARE)
  287.   6.112 HEALTHCARE, BY BIOMARKER, 2024 TO 2035 (USD Billion)
  288.   6.113 HEALTHCARE, BY IMAGING MODALITY, 2024 (% SHARE)
  289.   6.114 HEALTHCARE, BY IMAGING MODALITY, 2024 TO 2035 (USD Billion)
  290.   6.115 HEALTHCARE, BY GENETIC MUTATION, 2024 (% SHARE)
  291.   6.116 HEALTHCARE, BY GENETIC MUTATION, 2024 TO 2035 (USD Billion)
  292.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  293. 7 LIST OF TABLES
  294.   7.1 LIST OF ASSUMPTIONS
  295.     7.1.1
  296.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  297.     7.2.1 BY TEST TYPE, 2025-2035 (USD Billion)
  298.     7.2.2 BY BIOMARKER, 2025-2035 (USD Billion)
  299.     7.2.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  300.     7.2.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  301.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  302.     7.3.1 BY TEST TYPE, 2025-2035 (USD Billion)
  303.     7.3.2 BY BIOMARKER, 2025-2035 (USD Billion)
  304.     7.3.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  305.     7.3.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  306.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  307.     7.4.1 BY TEST TYPE, 2025-2035 (USD Billion)
  308.     7.4.2 BY BIOMARKER, 2025-2035 (USD Billion)
  309.     7.4.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  310.     7.4.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  311.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  312.     7.5.1 BY TEST TYPE, 2025-2035 (USD Billion)
  313.     7.5.2 BY BIOMARKER, 2025-2035 (USD Billion)
  314.     7.5.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  315.     7.5.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  316.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  317.     7.6.1 BY TEST TYPE, 2025-2035 (USD Billion)
  318.     7.6.2 BY BIOMARKER, 2025-2035 (USD Billion)
  319.     7.6.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  320.     7.6.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  321.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  322.     7.7.1 BY TEST TYPE, 2025-2035 (USD Billion)
  323.     7.7.2 BY BIOMARKER, 2025-2035 (USD Billion)
  324.     7.7.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  325.     7.7.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  326.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  327.     7.8.1 BY TEST TYPE, 2025-2035 (USD Billion)
  328.     7.8.2 BY BIOMARKER, 2025-2035 (USD Billion)
  329.     7.8.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  330.     7.8.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  331.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  332.     7.9.1 BY TEST TYPE, 2025-2035 (USD Billion)
  333.     7.9.2 BY BIOMARKER, 2025-2035 (USD Billion)
  334.     7.9.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  335.     7.9.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  336.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  337.     7.10.1 BY TEST TYPE, 2025-2035 (USD Billion)
  338.     7.10.2 BY BIOMARKER, 2025-2035 (USD Billion)
  339.     7.10.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  340.     7.10.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  341.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  342.     7.11.1 BY TEST TYPE, 2025-2035 (USD Billion)
  343.     7.11.2 BY BIOMARKER, 2025-2035 (USD Billion)
  344.     7.11.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  345.     7.11.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  346.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  347.     7.12.1 BY TEST TYPE, 2025-2035 (USD Billion)
  348.     7.12.2 BY BIOMARKER, 2025-2035 (USD Billion)
  349.     7.12.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  350.     7.12.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  351.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  352.     7.13.1 BY TEST TYPE, 2025-2035 (USD Billion)
  353.     7.13.2 BY BIOMARKER, 2025-2035 (USD Billion)
  354.     7.13.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  355.     7.13.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  356.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  357.     7.14.1 BY TEST TYPE, 2025-2035 (USD Billion)
  358.     7.14.2 BY BIOMARKER, 2025-2035 (USD Billion)
  359.     7.14.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  360.     7.14.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  361.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  362.     7.15.1 BY TEST TYPE, 2025-2035 (USD Billion)
  363.     7.15.2 BY BIOMARKER, 2025-2035 (USD Billion)
  364.     7.15.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  365.     7.15.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  366.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  367.     7.16.1 BY TEST TYPE, 2025-2035 (USD Billion)
  368.     7.16.2 BY BIOMARKER, 2025-2035 (USD Billion)
  369.     7.16.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  370.     7.16.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  371.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  372.     7.17.1 BY TEST TYPE, 2025-2035 (USD Billion)
  373.     7.17.2 BY BIOMARKER, 2025-2035 (USD Billion)
  374.     7.17.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  375.     7.17.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  376.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  377.     7.18.1 BY TEST TYPE, 2025-2035 (USD Billion)
  378.     7.18.2 BY BIOMARKER, 2025-2035 (USD Billion)
  379.     7.18.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  380.     7.18.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  381.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  382.     7.19.1 BY TEST TYPE, 2025-2035 (USD Billion)
  383.     7.19.2 BY BIOMARKER, 2025-2035 (USD Billion)
  384.     7.19.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  385.     7.19.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  386.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  387.     7.20.1 BY TEST TYPE, 2025-2035 (USD Billion)
  388.     7.20.2 BY BIOMARKER, 2025-2035 (USD Billion)
  389.     7.20.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  390.     7.20.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  391.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  392.     7.21.1 BY TEST TYPE, 2025-2035 (USD Billion)
  393.     7.21.2 BY BIOMARKER, 2025-2035 (USD Billion)
  394.     7.21.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  395.     7.21.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  396.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  397.     7.22.1 BY TEST TYPE, 2025-2035 (USD Billion)
  398.     7.22.2 BY BIOMARKER, 2025-2035 (USD Billion)
  399.     7.22.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  400.     7.22.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  401.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  402.     7.23.1 BY TEST TYPE, 2025-2035 (USD Billion)
  403.     7.23.2 BY BIOMARKER, 2025-2035 (USD Billion)
  404.     7.23.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  405.     7.23.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  406.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  407.     7.24.1 BY TEST TYPE, 2025-2035 (USD Billion)
  408.     7.24.2 BY BIOMARKER, 2025-2035 (USD Billion)
  409.     7.24.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  410.     7.24.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  411.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  412.     7.25.1 BY TEST TYPE, 2025-2035 (USD Billion)
  413.     7.25.2 BY BIOMARKER, 2025-2035 (USD Billion)
  414.     7.25.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  415.     7.25.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  416.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  417.     7.26.1 BY TEST TYPE, 2025-2035 (USD Billion)
  418.     7.26.2 BY BIOMARKER, 2025-2035 (USD Billion)
  419.     7.26.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  420.     7.26.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  421.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  422.     7.27.1 BY TEST TYPE, 2025-2035 (USD Billion)
  423.     7.27.2 BY BIOMARKER, 2025-2035 (USD Billion)
  424.     7.27.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  425.     7.27.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  426.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  427.     7.28.1 BY TEST TYPE, 2025-2035 (USD Billion)
  428.     7.28.2 BY BIOMARKER, 2025-2035 (USD Billion)
  429.     7.28.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  430.     7.28.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  431.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  432.     7.29.1 BY TEST TYPE, 2025-2035 (USD Billion)
  433.     7.29.2 BY BIOMARKER, 2025-2035 (USD Billion)
  434.     7.29.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  435.     7.29.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  436.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  437.     7.30.1 BY TEST TYPE, 2025-2035 (USD Billion)
  438.     7.30.2 BY BIOMARKER, 2025-2035 (USD Billion)
  439.     7.30.3 BY IMAGING MODALITY, 2025-2035 (USD Billion)
  440.     7.30.4 BY GENETIC MUTATION, 2025-2035 (USD Billion)
  441.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  442.     7.31.1
  443.   7.32 ACQUISITION/PARTNERSHIP
  444.     7.32.1

Healthcare Market Segmentation

Healthcare By Test Type (USD Billion, 2025-2035)

  • Biomarker Tests
  • Imaging Tests
  • Genetic Tests
  • Pathology Tests

Healthcare By Biomarker (USD Billion, 2025-2035)

  • CA-125
  • HE4
  • ROMA
  • OVX1
  • PAX2
  • MMP7

Healthcare By Imaging Modality (USD Billion, 2025-2035)

  • Ultrasound
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET)

Healthcare By Genetic Mutation (USD Billion, 2025-2035)

  • BRCA1
  • BRCA2
  • TP53
  • PTEN
  • ARID1A
  • CHEK2

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions